Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SMDPY and 80,000+ other tickers.
See exactly how SMDPY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SMDPY and 80,000+ other tickers.
Sumitomo Pharma Co., Ltd. operates as a global entity focused on the development, manufacturing, and distribution of a diverse range of products. Its primary offerings include pharmaceutical drugs, food components and additives, and veterinary treatments. The company's reach extends across Japan, North America, China, and various other international markets. The pharmaceutical segment boasts an extensive portfolio addressing numerous medical conditions. This encompasses therapeutic agents for neurological disorders like Parkinson's disease and epilepsy, psychiatric conditions such as…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells. This Phase 1/2a, open-label, single-arm, uncontrolled, dose-escalation study (NCT06891885) is evaluating tw.
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective menin inhibitor for the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement, to allow for interim analysis. Achieving this milestone will enable SMPA to obtain results of the interim analysis by the end of calendar year 2026. These results.
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.